Full Name
Dr. Meletios A. Dimopoulos MD
Job Title
Professor of Therapeutics-Hematology-Oncology
Company/Affiliation
National and Kapodistrian University of Athens
Speaker Bio
Meletios Athanasios (Thanos) Dimopoulos, MD, is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece. He was the Rector of the National and Kapodistrian University of Athens from February 2015 until August 2023. He has been a member of the Board of the International Myeloma Society and the Chairman of the Greek Myeloma Study Group. Currently, he is the Chairman of the Balkan Myeloma Study Group, a member of the Board of the European Myeloma Network, a member of the Scientific Committee of the European School of Haematology, a member of the SOHO Educational Committee, and a member of the Editorial Board of Expert Review of Hematology. Effective January 2026, he will be a member of the Editorial Board of the Journal of Clinical Oncology.
As of November 2025, he has published more than 1,600 manuscripts in peer-reviewed journals, and his h-index (Google Scholar) is 179, with 159,393 citations (Web of Knowledge ISI: h-index 146, citations 117,647). His particular interest is in hematologic malignancies (especially plasma cell dyscrasias) and solid tumors, especially gynecologic and genitourinary tumors.
He is a recipient of the Robert A. Kyle Award for Outstanding Contributions to Waldenström’s Macroglobulinemia (May 2003), a recipient of the Waldenström Award for Myeloma Research of the International Myeloma Society (March 2017), and a recipient of the CoMy Excellence Award (May 2017). In August 2017, he was given the title "Officier dans l'Ordre des Palmes Académiques" (République Française, Ministère de l'Éducation Nationale). In May 2018, he was elected as “membre associé étranger” of the National Academy of Medicine of France. He also received the Robert Kyle Life Achievement Award (June 2019), the Distinguished Alumnus Award from the MD Anderson Cancer Center, Houston, TX, USA (January 2020), the Medal of the Grand Commander of the Order of the Phoenix awarded by the President of the Hellenic Republic (February 2020), and the Title of Doctor Honoris Causa by the University of Belgrade (October 2022). In October 2024, he was appointed Adjunct Professor at the College of Medicine, Korea University, Seoul, South Korea. In May 2025, he was elected a member of the Academia Europaea (Section of Basic and Clinical Translational Sciences). He is a panel member of the European Research Council Advanced Grant Evaluation 2025.
As of November 2025, he has published more than 1,600 manuscripts in peer-reviewed journals, and his h-index (Google Scholar) is 179, with 159,393 citations (Web of Knowledge ISI: h-index 146, citations 117,647). His particular interest is in hematologic malignancies (especially plasma cell dyscrasias) and solid tumors, especially gynecologic and genitourinary tumors.
He is a recipient of the Robert A. Kyle Award for Outstanding Contributions to Waldenström’s Macroglobulinemia (May 2003), a recipient of the Waldenström Award for Myeloma Research of the International Myeloma Society (March 2017), and a recipient of the CoMy Excellence Award (May 2017). In August 2017, he was given the title "Officier dans l'Ordre des Palmes Académiques" (République Française, Ministère de l'Éducation Nationale). In May 2018, he was elected as “membre associé étranger” of the National Academy of Medicine of France. He also received the Robert Kyle Life Achievement Award (June 2019), the Distinguished Alumnus Award from the MD Anderson Cancer Center, Houston, TX, USA (January 2020), the Medal of the Grand Commander of the Order of the Phoenix awarded by the President of the Hellenic Republic (February 2020), and the Title of Doctor Honoris Causa by the University of Belgrade (October 2022). In October 2024, he was appointed Adjunct Professor at the College of Medicine, Korea University, Seoul, South Korea. In May 2025, he was elected a member of the Academia Europaea (Section of Basic and Clinical Translational Sciences). He is a panel member of the European Research Council Advanced Grant Evaluation 2025.
Speaking At
